The American Society of Clinical Oncology (ASCO) recently updated clinical practice guidelines on the treatment and prevention of venous thromboembolism (VTE) in patients with cancer. Although several new studies have been reported, many questions remain about the close relationship between VTE and malignant disease. The risk of VTE among patients with cancer continues to increase and is clearly linked to patient-, disease-and treatment-specific factors. In general, VTE among patients with cancer is treated in a similar fashion to that in other patient populations. However, the greater risk of VTE in patients with cancer, the multitude of risk factors, and the greater risk of VTE recurrence and mortality among patients with cancer pose important challenges for surgeons, oncologists, and other providers.
T he relationship between cancer and thrombosis was fırst described more than 150 years ago, when a French doctor, Armand Trousseau, fırst described an association between the occurrence of thrombosis and a yet-undiagnosed cancer. 1 Patients with malignancy may display many types of hemostatic disorders, ranging from hemorrhages to thrombosis and disseminated intravascular coagulation. The results of laboratory tests able to detect subtle alterations of the hemostatic balance demonstrate the presence of a subclinical hypercoagulable state during the development of malignancy. These tests measure specifıc products of clotting reactions in plasma, including prothrombin fragment 1ϩ2, fıbrinopeptide A, thrombin-antithrombin complexes, plasmin-antiplasmin complexes, and D-dimer, which tend to be universally increased in patients with cancer, 1 indicating the presence of in vivo thrombin generation and fıbrin formation and fıbrinolysis. In addition, the presence of activated vascular cells in the circulation of patients with malignancy is demonstrated by the results of laboratory assays for the specifıc measure of markers of activation of hemostatic cellular components, such as platelets, leukocytes, and endothelial cells. In this setting, the detection of circulating microparticles (MP), shed by platelets, leukocytes, the vascular endothelium, or directly by cancer cells, is gaining increasing interest for their involvement in the occurrence of the cancerassociated hypercoagulable state. In addition, MP-enriched prothrombotic and proangiogenic factors are new important players in supporting tumor growth. 2 Overall these hemostatic alterations characterize the hypercoagulable state of these patients, which typically can worsen with the start of antitumor therapies and with cancer progression, consistent with a relation between tumor burden and blood-clotting activation. 1 
MECHANISMS
In addition to clinical factors summarized below, the mechanisms of thrombosis in cancer involve several biologic factors produced by the malignant cells capable of activating the hemostatic system. 3 In the last decade, molecular studies of experimental models of human cancer (e.g., hepatoma, brain tumors, colon cancer) demonstrated that oncogene and repressor gene-mediated neoplastic transformation (i.e., activation of hepatocyte growth factor receptor, loss of phosphatase and tensin homolog, induction of V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, and loss of protein 53) activate clotting as an integral feature of neoplastic transformation. 4 Furthermore, a mutation of epidermal growth factor receptor gene renders cancer cells hypersensitive to the action of coagulation proteins, such as tissue factor (TF); as a result, a microenvironment promoting tumor growth is generated. 5 These data support the concept of a complex scenario in which oncogenic events drive the procoagulant conversion of tumor cells. Studies conducted in different types of cancers show that malignant cells can activate the hemostatic system in several ways. The principal mechanisms include the expression of procoagulant factors including procoagulant proteins, such as TF and cancer procoagulant (CP), MP, inflammatory cytokines, and adhesion molecules 3 (Fig. 1) . The same mechanisms can contribute to tumor development and progression.
The most characterized tumor procoagulant is TF, a transmembrane glycoprotein that is the primary initiator of normal blood coagulation. It forms a complex with factor VIIa to trigger blood coagulation by proteolytically activating factors IX and X. TF is constituently expressed by malignant cells of a variety of cancers, including many solid tumors as well as leukemia blast cells. TF activity on tumor cells can be potentiated by the expression of anionic phospholipids on the outer leaflet of the cell membrane 6 and the secretion of heparanase. The main function of heparanase is to degrade heparin sulfates of extracellular matrix, thereby promoting tumor invasion and metastasis. However, heparanase can also interact with TF pathway inhibitor (TFPI) on the cell surface, leading to dissociation of TFPI from the cell membrane of endothelial and tumor cells that results in an increased cell-surface TF activity. 7 Another tumor procoagulant is CP, a cysteine protease that directly activates factor X independently of factor VII. CP is synthesized by malignant cells, and its activity has been found in extracts of different tumors. 8 Of interest, in patients with acute promyelocytic leukemia, CP is expressed by bone marrow and blast cells at the onset of disease, but disappears when remission is reached. 3 CP also has been studied in patients with different types of solid tumors. Tumor cells are capable to release MP, the small membrane vesicles of 0.1 to 1.0 mi in diameter mainly composed of lipids, proteins, and nucleic acids. High MP levels have been detected in patients with solid tumors (e.g., pancreas, breast, lung, colorectal cancers) 9,10 as well as hematologic malignancies (e.g., acute leukemia, multiple myeloma, essential thrombocythemia). MP contribute to intravascular thrombin generation by exposure of phosphatidylserine and TF, and may explain the increased level of TG in the circulation of patients with cancer. 10, 11 MP of platelet origin were found higher in stage IV compared with stage I and stage II/III gastric cancer, showing the highest diagnostic accuracy for metastasis prediction. 12 Tumor cells can also interact with the host fıbrinolytic system, because of the expression of plasminogen activators,
KEY POINTS
⅐ Cancer tissues express a prothrombotic phenotype. ⅐ Clotting proteins affect cancer progression. ⅐ Patients with cancer are at increased risk for VTE but incidence rates are highly variable. ⅐ Risk can reliably be predicted using a validated riskassessment tool. ⅐ Venous thromboembolism in patients with cancer should be treated with low-molecular weight heparin initially with extended secondary prophylaxis for at least 4 to 6 months. ⅐ Routine thromboprophylaxis is not recommended for patients with ambulatory cancer except in select high-risk settings. their inhibitors (such as plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2), and receptors such as the urokinase receptor 3 and of annexin II, a coreceptor for plasminogen and tissue plasminogen activator. In acute promyelocytic leukemia, the increased annexin II expression has been linked to an excessive activation of fıbrinolysis. 13 
CLOTTING PROTEINS AND TUMOR PROGRESSION
The clotting system activation may play several roles in tumor growth and metastasis. Procoagulant proteins such as TF and factor VIIa, activated factor X, thrombin, and fıbrin have the capacity to support the malignant process by promoting neoangiogenesis and formation of metastases. Fibrin favors both thrombogenesis and tumor progression through several mechanisms, i.e., it provides the scaffold for new vessel formation, induces endothelial expression of TF and IL-8, and protects the proangiogenic growth factors bFGF, VEGF, and insulin-like growth factor-1 from proteolytic degradation. Finally, localized fıbrin deposition favors the metastatic process by stabilizing tumor-cell adhesion or tumor-cell-associated emboli to the endothelium. Thrombin and TF participate in tumor progression through clotting-independent mechanisms mediated by protease-activated receptors (PAR) expressed by platelets, tumor cells, endothelial cells, vascular smooth muscle cells, and macrophages. Thrombin activation of PARs stimulates growth factors, chemokines, and extracellular proteins release that promote tumor-cell proliferation and migration. 14 Moreover, TF promotes tumor invasion and metastasis by the capacity of TF/factor VIIa complex to cooperate with TFPI expressed by tumor vessels in inducing cell adhesion and migration by a thrombin-independent circle. 3 Activated platelets facilitate the adhesion of tumor cells to endothelial cells favoring their migration through the vessel wall by the release of heparanase activity. Additionally tumor-cell-associated platelets may support metastasis formation by protecting tumor cells from attack by innate immune cells. 15 Independently from thrombin, platelets can be directly activated by tumor cells through the release of proaggregating substances or adhesion mechanisms. 16 The formation of tumor-cell-platelet thrombi may support metastasis formation by preventing interactions between tumor and innate immune cells. 15 Activated leukocytes, particularly neutrophils, promote tumor growth and metastasis, and can adhere to tumor cells facilitating their migration across the endothelium. 3 Platelet-released MP display highproangiogenic activity because of their unique content of angiogenesis-stimulating agents derived from platelet alphagranules, together with the expression of adhesion molecules, and the capacity to induce proangiogenic factor release by tumor cells. TF expressed by MP might represent another important mechanism involving MP in tumor progression. 2 Moreover, intracellular transfer of MP may occur between cancer cells, leading to a horizontal propagation of oncogenes and their associated transforming phenotype. 17 Clearly, a reciprocal cancer-thrombosis connection exists, by which cancer cells support clot formation, and clotting proteins support cancer growth and dissemination.
TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER
ASCO developed evidence-based VTE guidelines in 2007 specifıcally for patients with cancer 18 (Table 1) . ASCO Guidelines have recently been updated after an exhaustive systematic review of the relevant literature on this topic since the original were published. 19 The ASCO guidelines recommend low-molecular weight heparins (LMWH) for both the initial 5 to 10 days of anticoagulation as well as long-term secondary prevention of recurrence for at least 6 months in patients with cancer with newly diagnosed VTE ( Table 2) . select high-risk patients with active malignancy and continuing on chemotherapy may be considered for indefınite anticoagulation to reduce the risk of recurrent VTE and its complications. The risk of VTE recurrence, bleeding, and mortality associated with incidental VTE appears similar to patients with cancer with symptomatic VTE. 20 The consensus opinion of the ASCO guidelines panel is that incidental pulmonary embolism and deep venous thrombosis (DVT) should be treated in the same manner as symptomatic VTE.
PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER Hospitalized Medical Patients
The literature review identifıed three recent randomized controlled trials (RCTs) of thromboprophylaxis in medically ill nonsurgical (medical) inpatients. [21] [22] [23] The EXCLAIM trial evaluated extended prophylaxis. 21 Although failing to reach statistical signifıcance, the rate of symptomatic and screen-detected VTE and VTE-related deaths with certoparin (11%) was less than with unfractionated heparin (UFH) (18%). 22 Although patients with cancer could participate in the CERTIFY trial again comparing certoparin with UFH, no signifıcant difference in event rates was observed. 23 Although representing largely an older population, less than 10% of patients in these trials were patients with cancer. Despite the paucity of cancer-specifıc data, the ASCO guidelines recommend that hospitalized patients with acute medical illness, reduced mobility with no bleeding, or other contraindication should receive prophylactic anticoagulation. Hull et al. randomly assigned acutely ill medical inpatients, mostly with substantial immobility, to enoxaparin or a placebo for 4 weeks following an initial 10 days of enoxaparin 3.2 Prophylaxis should be commenced preoperatively.
3.3 Mechanical methods may be added to pharmacologic thromboprophylaxis, but should not be used as monotherapy for VTE prevention unless pharmacologic methods are contraindicated because of active bleeding or high bleeding risk.
3.4 A combined regimen of pharmacologic and mechanical prophylaxis may improve efficacy, especially in the highest-risk patients.
3.5 Pharmacologic thromboprophylaxis should be continued for at least 7-10 d in all patients. Extended prophylaxis with LMWH for up to 4 wk postoperatively should be considered for patients undergoing major abdominal or pelvic surgery for cancer who have high-risk features such as restricted mobility, obesity, history of VTE, or with additional risk factors.
Treatment and Secondary Prophylaxis
4.1 LMWH is preferred over UFH for the initial 5 to 10 d of anticoagulation for the patient with cancer with newly diagnosed VTE who does not have severe renal impairment (defined as creatinine clearance Ͻ30 mL/min).
4.2 For long-term anticoagulation, LMWH for at least 6 mo is preferred because of improved efficacy over Vitamin K antagonists. Vitamin K antagonists are an acceptable alternative for long-term therapy if LMWH is not available.
4.3 Anticoagulation with LMWH or Vitamin K antagonist beyond the initial 6 mo may be considered for select patients with active cancer, such as those with metastatic disease or those receiving chemotherapy.
4.4
The insertion of a vena cava filter is only indicated for patients with contraindications to anticoagulant therapy. It may be considered as an adjunct to anticoagulation in patients with progression of thrombosis (recurrent VTE or extension of existing thrombus) despite maximal therapy with LMWH.
4.5 For patients with central nervous system malignancies, anticoagulation is recommended for established VTE as described for other patients with cancer. Careful monitoring is necessary to limit the risk of hemorrhagic complications.
4.6 Use of novel oral anticoagulants for either prevention or treatment of VTE in patients with cancer is not recommended at this time.
4.7 Incidental PE and DVT should be treated in the same manner as symptomatic VTE. Treatment of splanchnic or visceral vein thrombi diagnosed incidentally should be considered on a case-by-case basis, considering potential benefits and risks of anticoagulation.
Anticoagulation and Survival 5.1 Anticoagulants are not recommended to improve survival in patients with cancer without VTE.
5.2
Patients with cancer should be encouraged to participate in clinical trials designed to evaluate anticoagulant therapy as an adjunct to standard anticancer therapies.
Risk Assessment
6.1 Patients with cancer should be assessed for VTE risk at the time of chemotherapy initiation and periodically thereafter.
6.2 In the outpatient setting, risk assessment can be conducted based on a validated risk assessment tool.
6.3 Solitary risk factors, including biomarkers or cancer site, do not reliably identify patients with cancer at high risk of VTE.
6.4 Oncologists should educate patients regarding VTE, particularly in settings that increase risk such as major surgery, hospitalization, and while receiving systemic antineoplastic therapy. Patient education should at least include a discussion of the warning signs and symptoms of VTE, including leg swelling or pain, suddenonset chest pain, and shortness of breath.
Abbreviations: d, day; DVT, deep venous thrombosis; LMWH, low-molecular weight heparin; mo, month; PE, pulmonary embolism; RCT, randomized controlled trial; UFH, unfractionated heparin; VTE, venous thromboembolism; wk, week.
LYMAN, KHORANA, AND FALANGA e340or placebo. 21 Although screening detected VTE, and fatal pulmonary embolism were detected less with enoxaparin (4.0%) than placebo (2.5%); absolute risk reduction was small and no signifıcant difference in overall mortality was observed. Although approximately 15% of patients had malignant disease, cancer-specifıc data have not been reported. The MAGELLAN trial randomly assigned acutely ill medical patients to enoxaparin for 10 days and to rivaroxaban for 35 days, demonstrating a slight reduction in VTE risk along with a small but signifıcant increase in major bleeding (p ϭ 0.03). 24 
Surgical Patients with Cancer
The literature review identifıed three RCTs evaluating perioperative prophylaxis in patients undergoing abdominal or pelvic surgery. Sakon et al. demonstrated the superiority of enoxaparin prophylaxis to intermittent pneumatic compression in patients with cancer undergoing abdominal Abbreviations: aPTT, activated partial thromboplastin time; bid, twice daily; d, day; h, hour; INR, international normalized ratio; IV, intravenous; kg, kilogram; mg, milligram; PO, oral; post-op, post-operatively; pre-op, pre-operatively; q, every; U, unit; VTE, venous thromboembolism; wks, weeks. * All doses are given as subcutaneous injections except as indicated. ** When neuraxial anesthesia or analgesia is planned, prophylactic doses of once-daily LMWH should not be given within 10 to 12 hours prior to the procedure/instrumentation (including epidural catheter removal). After the surgery, the first dose of LMWH can be given 6 to 8 hours postoperatively. After catheter removal, the first dose of LMWH can be given no earlier than 2 hours afterwards. a.) Duration for medical patients is for the length of hospital stay or is fully ambulatory; for surgical patients, prophylaxis should be continued for at least 7 to 10 days. Extended prophylaxis for up to 4 weeks should be considered for high-risk patients. b.) Unfractionated heparin 5,000 U every 12 hours has also been used but appears to be less effective. c.) This drug is not approved by the U.S. Food and Drug Administration for this indication. d.) Parenteral anticoagulants should overlap with warfarin for 5 to 7 days minimum and continued until INR is in the therapeutic range for 2 consecutive days. e.) Twice-daily dosing may be more efficacious than once-daily dosing for enoxaparin based on post-hoc data. f.) Optimal dose unclear in patients Ͼ120 kg. g.) Unfractionated heparin infusion rate should be adjusted to maintain the aPTT within the therapeutic range in accordance with local protocol to correspond with a heparin level of 0.3 to 0.7 U/mL using a chromogenic Xa assay. h.) Total duration of therapy depends on clinical circumstances. See text for more detailed discussion. j.) This drug is not available in the United States. o.) Dependent on significant renal clearance; avoid in patients with creatinine clearance Յ 30 mL/minute or adjust dose based on antifactor Xa levels. p.) This is the only LMWH with FDA approval for extended therapy to prevent recurrent thrombosis in patients with cancer.
laparotomy. 25 The SAVE-ABDO trial randomly assigned patients undergoing major surgery mostly for cancer to either semuloparin starting before surgery to enoxaparin started postoperatively. 26 Although major bleeding was less common with semuloparin, no signifıcant difference in the risk of VTE or all-cause mortality was observed. Likewise, in the Simonneau study, patients with colorectal cancer randomly assigned to preoperative nadroparin compared with enoxaparin experienced less major bleeding but no difference in rates of symptomatic or asymptomatic VTE. 27 In the absence of contraindications, patients with cancer undergoing major surgery should be considered for thromboprophylaxis with either UFH or LMWH, preferably starting preoperatively and continuing for 7 to 10 days. Systematic reviews of extended prophylaxis with LMWH compared with the placebo or untreated controls for up to 4 weeks have been reported. [28] [29] [30] Subgroup analyses in patients with cancer demonstrated a decrease in asymptomatic and symptomatic VTE with no signifıcant difference in major bleeding rates. 28, 29 ASCO guidelines recommend extended postoperative prophylaxis in patients undergoing major cancer surgery with LMWH for up to 4 weeks in high-risk patients such as those with restricted mobility, obesity, and history of VTE.
Ambulatory Patients Receiving Chemotherapy
Nine RCTs of LMWH thromboprophylaxis compared with a placebo or untreated controls in ambulatory patients with advanced cancer have been reported. Signifıcant reductions in the relative risk (RR) of VTE were observed in SAVE-ONCO. 31 In a meta-analysis of all RCTs, Kuderer et al. reported an RR for symptomatic VTE across trials with LMWH compared with controls of 0.47 (0.36 -0.61; p Ͻ 0.001) but an absolute reduction in VTE risk of 2.8% (1.8%-3.7%;p Ͻ 0.001). 32 The most dramatic effects on the absolute risk of VTE were observed in the FRAGEM and CONKO-004 trials in patients with advanced pancreatic cancer receiving specifıed chemotherapy [33] [34] [35] with a combined reduction in absolute VTE risk of 12.5%. 32 FRAGEM was a phase IIb RCT of therapeutic-dose dalteparin compared with no prophylaxis in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. 33 CONKO-004 randomly assigned patients with stage IV pancreatic cancer being treated with gemcitabine-based chemotherapy to enoxaparin at half-therapeutic dose or no thromboprophylaxis. 35 On the basis of the limitations in these trials and the small incremental benefıt observed in most of the ambulatory VTE prophylaxis trials, the ASCO Guidelines panel concluded that routine anticoagulation prophylaxis in ambulatory patients with cancer is not justifıed. Two trials of thromboprophylaxis in patients with multiple myeloma have also been reported. 36, 37 Palumbo et al. found no signifıcant differences in VTE or bleeding rates among thalidomide-treated patients randomly assigned to warfarin, low-dose aspirin, or enoxaparin. 37 Larocca likewise found no signifıcant difference in risk of VTE or major bleeding in patients with multiple myeloma treated with lenalidomidebased chemotherapy and randomly assigned to low-dose aspirin or enoxaparin. 36 Patients with multiple myeloma receiving thalidomide or lenalidomide along with chemotherapy and/or dexamethasone should receive thromboprophylaxis with either aspirin or LMWH for lower-risk patients and LMWH for higher-risk patients.
RISK ASSESSMENT
It is widely accepted that the prevalence of VTE in patients with cancer is substantially higher than in the general population. Because of marked variation in VTE risk across cancer types and between individual patients, the 2013 update of the ASCO guidelines recommends that patients with cancer should be assessed for VTE risk at the time of chemotherapy initiation and periodically thereafter.
Clinical Risk Factors
Clinical variables associated with VTE can be categorized as patient-related, cancer-related, and treatment-related. Patient-related risk factors include age (higher risk in older adults), race/ethnicity (higher risk in the black population and lower risk in Asian-Americans), and comorbid conditions including infection, pulmonary or renal disease, and obesity. Cancer-related risk factors include primary site, initial period after diagnosis (with highest rates in the fırst 3 to 6 months after diagnosis), histology (higher risk for patients with adenocarcinoma or higher grade) and, less consistently, advanced stage. The primary site of cancer is especially important, with highest rates of VTE observed in patients with brain, pancreas, stomach, kidney, ovary, and lung cancers and hematologic malignancies including lymphoma and myeloma. Treatment-related risk factors further add to risk of VTE in cancer. Patients with cancer receiving systemic chemotherapy have a several-fold increased risk of VTE compared with the general population. The risk is higher with specifıc chemotherapy agents such as cisplatin. 38 Bevacizumab-containing regimens are clearly associated with increased risk for arterial events (hazard ratio 2.0, 95% CI:1.05-3.75). However, despite popular perception, it is unclear whether there is an increased risk of venous events. 39 In a meta-analysis, VTE occurred in 11.9% of patients treated with bevacizumab (RR:1.33, 95% CI:1.13-1.56; p ϭ 0.001). 40 However, patients with bevacizumab stay on treatment longer because of its effıcacy; in a subsequent reanalysis accounting for exposure time, the authors found no signifıcant association with VTE when time on therapy was included as a variable (RR 1.10, 95% CI: 0.89 -1.36) Sunitinib and sorafenib have also been associated with increased risk for arterial events (RR 3.03, 95% CI: 1.25-7.37) suggesting this may be a class effect for antiangiogenic agents. 41 
Biomarkers
Evidence of increased risk of VTE is strongest for components of the complete blood count: baseline (prechemotherapy) increased platelet counts (defıned as Ն 350,000/ mm 3 ), increased leukocyte counts (Ͼ 11,000/mm 3 ) and low hemoglobin (Ͻ10 g/dL) are all associated with chemotherapy-associated VTE. 42, 43 D-dimer is yet another widely studied and available biomarker, although it should be noted that many patients with cancer have increased levels and there is no consensus on the level predictive of higher risk. Increased D-dimer levels (defıned as greater than the 75 th percentile for the study population) were associated with increased VTE (HR 1.8; 95% CI: 1.0 -3.2; p ϭ 0.048) in a prospective cohort study from Vienna. 44 In a novel approach, D-dimer was used to screen for VTE in patients with presumed ovarian cancer. 45 The mean D-dimer level was 4.1 g/ mL. Subsequent venous ultrasonography revealed DVT in 16.1% of patients but none were found to have developed DVT if they had a D-dimer level of lower than 1.5 g/mL. TF is the physiologic initiator of coagulation and found to be widely expressed in a variety of malignancies and can be detected in the systemic circulation of patients with cancer. Although initial reports suggested a signifıcant association of increased TF with subsequent VTE, recent larger studies have failed to confırm its value as a biomarker except perhaps in pancreatic cancer. 46 
Risk Assessment Tools
The identifıcation of multiple factors associated with VTE spurred the development of a risk score that utilizes a combination of fıve easily available clinical and laboratory variables (Table 3) . 47 This risk score for VTE was derived from a development cohort of 2,701 patients and then validated in an independent cohort of 1,365 patients from a prospective registry. This model has now been externally validated by the Vienna study in 819 patients with cancer. 48 The 6-month cumulative probabilities of developing VTE in this external study population were 1.5% (score of 0), 3.8% (score of 1), 9.4% (score of 2), and 17.7% (score Ն3). Multiple other retrospective and prospective studies have further validated this score, although rates vary between studies because of various patient selection and follow-up periods. 49 Current ASCO guidelines recommend that risk assessment in the outpatient setting be conducted using this validated risk score.
Interestingly, in addition to prognostication, the risk score appears to also be predictive of benefıt from prophylaxis. When applied to the study population of a large randomized trial of semuloparin for outpatient prophylaxis of patients with cancer on treatment, rates in the placebo arm were higher and risk reduction was therefore greater in high-risk patients (5.4% in the placebo arm vs. 1.4% in the semuloparin arm, for score Ն 3 [HR 0.27] compared with 1.3% vs. 1%, respectively for score ϭ 0 [HR 0.71]). 50 Similarly, when applied to the study population of a randomized trial of outpatient prophylaxis using nadroparin, the number needed to treat to prevent one thromboembolic event fell from 50 for the full population to 15 for a high-risk population defıned by the risk score. 51 A prospective study of outpatient thromboprophylaxis in high-risk patients on the basis of the risk score is currently ongoing. 
